Alzheimer's Disease: key endpoint results by drug

The key endpoints of Alzheimer's Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Alzheimer's Disease page.

CDR-SB, change

CDR-SB, change in Alzheimer's Disease: 6 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
AGB1010.91.1−0.2220 mg · wk 78 · n 81NCT03486938 Phase 2/3, primary
Donanemab1.21.6−0.4wk 76 · n 93NCT03367403 Phase 2, secondary
Emestedastat0.30.2+0.1wk 12 · n 85NCT02727699 Phase 2, secondary
Lecanemab1.21.5−0.310 mg/kg Monthly · wk 78 · n 246NCT01767311 Phase 2, secondary
Masupirdine11.2−0.2100 mg · wk 26 · n 176NCT02580305 Phase 2, secondary
Pegipanermin0.20.3−0.11.0 mg/kg · wk 24 · n 134NCT05318976 Phase 2, secondary

Drugs checked with no result here: 12 not reported, 9 not posted, 11 trial running.

ADAS-Cog11, change

ADAS-Cog11, change in Alzheimer's Disease: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Buntanetap-2.2-2.3+0.130 mg · wk 12 · n 79NCT05686044 Phase 2/3, primary
Hydromethylthionine mesylate1.31.7−0.416 mg/day · wk 52 · n 189NCT03446001 Phase 3, primary
Masupirdine2.52.6−0.1100 mg · wk 26 · n 176NCT02580305 Phase 2, primary
Tricaprilin0.6a0+0.6wk 26NCT01741194 Phase 2/3, primary

Drugs checked with no result here: 13 trial running, 14 not reported, 7 not posted.

ADCS-ADL, change

ADCS-ADL, change in Alzheimer's Disease: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Buntanetap0.12.0−1.930 mg · wk 12 · n 76NCT05686044 Phase 2/3, secondary
Masitinib1.0a-0.8+1.8masitinib 4.5 mg/kg/day · wk 24NCT01872598 Phase 3, primary
Masupirdine-3.4-4.4+1100 mg · wk 26 · n 176NCT02580305 Phase 2, secondary
Sodium oligomannate-0.5-1.1+0.6900mg · wk 24 · n 83NCT01453569 Phase 2, secondary

Drugs checked with no result here: 13 trial running, 14 not reported, 7 not posted.

MMSE, change

MMSE, change in Alzheimer's Disease: 5 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
AGB101-2.2-1.9−0.3220 mg · wk 78 · n 81NCT03486938 Phase 2/3, secondary
Buntanetap-1.41.1−2.5Low dose · wk 3 · n 5NCT02925650 Phase 1/2, secondary
Donanemab-2.4-3.0+0.6wk 76 · n 91NCT03367403 Phase 2, secondary
Emestedastat0.2-0.2+0.4wk 12 · n 86NCT02727699 Phase 2, secondary
Masupirdine-1.1-1−0.1100 mg · wk 26 · n 176NCT02580305 Phase 2, secondary

Drugs checked with no result here: 11 trial running, 13 not reported, 9 not posted.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 38 approved or late-stage drugs with a featured trial in Alzheimer's Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.